Literature DB >> 20944671

Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients.

M Bardini, M Galbiati, A Lettieri, S Bungaro, T A Gorletta, A Biondi, G Cazzaniga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20944671     DOI： 10.1038/leu.2010.232

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  Molecular characterization of identical, novel MLL-EPS15 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia.

Authors:  Rishi S Kotecha; Jette Ford; Alex H Beesley; Denise Anderson; Catherine H Cole; Ursula R Kees
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

2.  Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Huining Kang; Carla S Wilson; Richard C Harvey; I-Ming Chen; Maurice H Murphy; Susan R Atlas; Edward J Bedrick; Meenakshi Devidas; Andrew J Carroll; Blaine W Robinson; Ronald W Stam; Maria G Valsecchi; Rob Pieters; Nyla A Heerema; Joanne M Hilden; Carolyn A Felix; Gregory H Reaman; Bruce Camitta; Naomi Winick; William L Carroll; ZoAnn E Dreyer; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

Review 3.  Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

Authors:  Alejandra Sanjuan-Pla; Clara Bueno; Cristina Prieto; Pamela Acha; Ronald W Stam; Rolf Marschalek; Pablo Menéndez
Journal:  Blood       Date:  2015-10-13       Impact factor: 22.113

4.  The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.

Authors:  David I Marks; Anthony V Moorman; Lucy Chilton; Elisabeth Paietta; Amir Enshaie; Gordon DeWald; Christine J Harrison; Adele K Fielding; Letizia Foroni; Anthony H Goldstone; Mark R Litzow; Selina M Luger; Andrew K McMillan; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Peter Wiernik; Hillard M Lazarus
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

5.  Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells.

Authors:  R Montes; V Ayllón; C Prieto; A Bursen; C Prelle; D Romero-Moya; P J Real; O Navarro-Montero; C Chillón; R Marschalek; C Bueno; P Menendez
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

6.  Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.

Authors:  Juan Ramón Tejedor; Clara Bueno; Meritxell Vinyoles; Paolo Petazzi; Antonio Agraz-Doblas; Isabel Cobo; Raúl Torres-Ruiz; Gustavo F Bayón; Raúl F Pérez; Sara López-Tamargo; Francisco Gutierrez-Agüera; Pablo Santamarina-Ojeda; Manuel Ramírez-Orellana; Michela Bardini; Giovanni Cazzaniga; Paola Ballerini; Pauline Schneider; Ronald W Stam; Ignacio Varela; Mario F Fraga; Agustín F Fernández; Pablo Menéndez
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

7.  Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.

Authors:  M Bardini; P S Woll; L Corral; S Luc; L Wittmann; Z Ma; L Lo Nigro; G Basso; A Biondi; G Cazzaniga; S E W Jacobsen
Journal:  Leukemia       Date:  2014-05-06       Impact factor: 11.528

8.  A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes.

Authors:  Joe R Harman; Ross Thorne; Max Jamilly; Marta Tapia; Nicholas T Crump; Siobhan Rice; Ryan Beveridge; Edward Morrissey; Marella F T R de Bruijn; Irene Roberts; Anindita Roy; Tudor A Fulga; Thomas A Milne
Journal:  Genome Res       Date:  2021-06-04       Impact factor: 9.043

9.  RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.

Authors:  Adam C Wilkinson; Erica Ballabio; Huimin Geng; Phillip North; Marta Tapia; Jon Kerry; Debabrata Biswas; Robert G Roeder; C David Allis; Ari Melnick; Marella F T R de Bruijn; Thomas A Milne
Journal:  Cell Rep       Date:  2013-01-24       Impact factor: 9.423

10.  The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.

Authors:  Alessia Casolaro; Josee Golay; Clara Albanese; Roberta Ceruti; Veronica Patton; Sabrina Cribioli; Alice Pezzoni; Marco Losa; Gemma Texido; Ursula Giussani; Francesco Marchesi; Nadia Amboldi; Barbara Valsasina; Silvia Bungaro; Gianni Cazzaniga; Alessandro Rambaldi; Martino Introna; Enrico Pesenti; Rachele Alzani
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.